N-myc amplification and its relationship to experimental therapy
Identifieur interne : 002928 ( Main/Exploration ); précédent : 002927; suivant : 002929N-myc amplification and its relationship to experimental therapy
Auteurs : Anne Livingstone [Royaume-Uni] ; Robert J. Mairs [Royaume-Uni]Source :
- Journal of Neuro-Oncology [ 0167-594X ] ; 1997-01-01.
English descriptors
Abstract
Abstract: N-myc amplification correlates with poor prognosis in neuroblastoma patients. Although the reason for this is unclear, it is possible that amplified N-myc confers resistance to certain agents used in the therapy of the disease. The acquisition of resistance to cytotoxic drugs in human tumour cells is multifactorial. One mechanism involved in the development of drug resistance is an increased efficiency of DNA repair. This could reduce the effectiveness of both cisplatin and etoposide (VP-16). Previous studies on human neuroblastoma cells have shown a relationship between N-myc copy number and cisplatin sensitivity [1]. We now report the response to VP-16 treatment of five human neuroblastoma cell lines with a range of N-myc gene copy numbers. After exposure of cells to drug for 24 hours, survival curves were constructed from clonogenic assay data and the iso-effective dose (the dose required to produce 1 log cell kill) was derived. The relationship between N-myc copy number or expression and response to VP-16 was assessed. A significant correlation was established between VP-16 resistance and copy number (r = 0.82; P < 0.05). However, no association was found between N-myc expression and isoeffective dose of VP-16. These results indicate that N-myc amplification may be responsible for treatment failure in those patients receiving cisplatin or VP-16.
Url:
DOI: 10.1023/A:1005773011779
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002808
- to stream Istex, to step Curation: 002808
- to stream Istex, to step Checkpoint: 001723
- to stream Main, to step Merge: 002978
- to stream Main, to step Curation: 002928
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">N-myc amplification and its relationship to experimental therapy</title><author><name sortKey="Livingstone, Anne" sort="Livingstone, Anne" uniqKey="Livingstone A" first="Anne" last="Livingstone">Anne Livingstone</name></author><author><name sortKey="Mairs, Robert J" sort="Mairs, Robert J" uniqKey="Mairs R" first="Robert J." last="Mairs">Robert J. Mairs</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:461CA267F406F686E1254344C84596408A44212B</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1023/A:1005773011779</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-6G5SM3GP-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002808</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002808</idno><idno type="wicri:Area/Istex/Curation">002808</idno><idno type="wicri:Area/Istex/Checkpoint">001723</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001723</idno><idno type="wicri:doubleKey">0167-594X:1997:Livingstone A:n:myc:amplification</idno><idno type="wicri:Area/Main/Merge">002978</idno><idno type="wicri:Area/Main/Curation">002928</idno><idno type="wicri:Area/Main/Exploration">002928</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">N-myc amplification and its relationship to experimental therapy</title><author><name sortKey="Livingstone, Anne" sort="Livingstone, Anne" uniqKey="Livingstone A" first="Anne" last="Livingstone">Anne Livingstone</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Departments of Clinical Physics and Radiation Oncology, University of Glasgow, CRC Beatson Laboratories, Garscube Estate, G61 1BD, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Mairs, Robert J" sort="Mairs, Robert J" uniqKey="Mairs R" first="Robert J." last="Mairs">Robert J. Mairs</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Departments of Clinical Physics and Radiation Oncology, University of Glasgow, CRC Beatson Laboratories, Garscube Estate, G61 1BD, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neuro-Oncology</title><title level="j" type="abbrev">J Neurooncol</title><idno type="ISSN">0167-594X</idno><idno type="eISSN">1573-7373</idno><imprint><publisher>Kluwer Academic Publishers</publisher><pubPlace>Boston</pubPlace><date type="published" when="1997-01-01">1997-01-01</date><biblScope unit="volume">31</biblScope><biblScope unit="issue">1-2</biblScope><biblScope unit="page" from="33">33</biblScope><biblScope unit="page" to="39">39</biblScope></imprint><idno type="ISSN">0167-594X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0167-594X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>N-myc</term><term>VP-16</term><term>apoptosis</term><term>cisplatin</term><term>neuroblastoma</term><term>radiation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: N-myc amplification correlates with poor prognosis in neuroblastoma patients. Although the reason for this is unclear, it is possible that amplified N-myc confers resistance to certain agents used in the therapy of the disease. The acquisition of resistance to cytotoxic drugs in human tumour cells is multifactorial. One mechanism involved in the development of drug resistance is an increased efficiency of DNA repair. This could reduce the effectiveness of both cisplatin and etoposide (VP-16). Previous studies on human neuroblastoma cells have shown a relationship between N-myc copy number and cisplatin sensitivity [1]. We now report the response to VP-16 treatment of five human neuroblastoma cell lines with a range of N-myc gene copy numbers. After exposure of cells to drug for 24 hours, survival curves were constructed from clonogenic assay data and the iso-effective dose (the dose required to produce 1 log cell kill) was derived. The relationship between N-myc copy number or expression and response to VP-16 was assessed. A significant correlation was established between VP-16 resistance and copy number (r = 0.82; P < 0.05). However, no association was found between N-myc expression and isoeffective dose of VP-16. These results indicate that N-myc amplification may be responsible for treatment failure in those patients receiving cisplatin or VP-16.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Écosse</li></region><settlement><li>Glasgow</li></settlement><orgName><li>Université de Glasgow</li></orgName></list><tree><country name="Royaume-Uni"><region name="Écosse"><name sortKey="Livingstone, Anne" sort="Livingstone, Anne" uniqKey="Livingstone A" first="Anne" last="Livingstone">Anne Livingstone</name></region><name sortKey="Mairs, Robert J" sort="Mairs, Robert J" uniqKey="Mairs R" first="Robert J." last="Mairs">Robert J. Mairs</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002928 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002928 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:461CA267F406F686E1254344C84596408A44212B
|texte= N-myc amplification and its relationship to experimental therapy
}}
| This area was generated with Dilib version V0.6.33. |  |